Endogenous and synthetic MMP inhibitors in CNS physiopathology

Progress in Brain Research

Volumn 214, Issue , 2014, Pages 313-351

  Baranger, Kévin ^a,b   Rivera, Santiago ^a   Liechti, Fabian D ^c   Grandgirard, Denis ^c   Bigas, Judit ^d   Seco, Jesús ^d   Tarrago, Teresa ^d,e   Leib, Stephen L ^c,f   Khrestchatisky, Michel ^a  

^a Mediterranée University   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^c UNIVERSITY OF BERN   (Switzerland)

^d Barcelona Science Park   (Spain)

^e INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^f SPIEZ LABORATORY   (Switzerland)

Author keywords

Alzheimer's disease; Bacterial meningitis; EAE; Multiple sclerosis; Synthetic MMP inhibitors

Indexed keywords

BATIMASTAT; BB 1001; COLLAGENASE; COLLAGENASE 3; DOXYCYCLINE; GELATINASE; GELATINASE A; GELATINASE B; ILOMASTAT; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE PROTEIN; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TNF 484; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL BEHAVIOR; APOPTOSIS; ARTICLE; ASTROCYTE; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM DISEASE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME REGULATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HIPPOCAMPUS; HUMAN; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL; NERVE CELL NECROSIS; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 84922270764     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63486-3.00014-1     Document Type: Chapter

References (227)

1. Acharya M.R., Venitz J., Figg W.D., Sparreboom A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist. Updat. 2004, 7:195-208.
2. Agrawal A., Romero-Perez D., Jacobsen J.A., Villarreal F.J., Cohen S.M. Zinc-binding groups modulate selective inhibition of MMPs. Chem Med Chem 2008, 3:812-820.
3. Agyeman P., Grandgirard D., Leib S. Pathogenesis and pathophysiology of bacterial infections. Infections of the Central Nervous System 2014, Lippincott Williams & Wilkins, Philadelphia, PA. fourth ed. M.W. Scheld, R.J. Whitley, C.M. Marra (Eds.).
4. Ahmad M., Takino T., Miyamori H., Yoshizaki T., Furukawa M., Sato H. Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases. J. Biochem. 2006, 139:517-526.
5. Alexander J.S., Harris M.K., Wells S.R., Mills G., Chalamidas K., Ganta V.C., et al. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult. Scler. 2010, 16:801-809.
6. Anthony D.C., Ferguson B., Matyzak M.K., Miller K.M., Esiri M.M., Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 1997, 23:406-415.
7. Apodaca G., Rutka J.T., Bouhana K., Berens M.E., Giblin J.R., Rosenblum M.L., et al. Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res. 1990, 50:2322-2329.
8. Asahi M., Wang X., Mori T., Sumii T., Jung J.C., Moskowitz M.A., et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 2001, 21:7724-7732.
9. Baba Y., Yasuda O., Takemura Y., Ishikawa Y., Ohishi M., Iwanami J., et al. Timp-3 deficiency impairs cognitive function in mice. Lab. Invest. 2009, 89:1340-1347.
10. Backstrom J.R., Lim G.P., Cullen M.J., Tokes Z.A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J. Neurosci. 1996, 16:7910-7919.
11. Bar-Or A., Nuttall R.K., Duddy M., Alter A., Kim H.J., Ifergan I., et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003, 126:2738-2749.
12. Bartsch J.W., Wildeboer D., Koller G., Naus S., Rittger A., Moss M.L., et al. Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-disintegrin ADAM8: evidence for a protease-regulated feedback loop in neuroprotection. J. Neurosci. 2010, 30:12210-12218.
13. Benesova Y., Vasku A., Novotna H., Litzman J., Stourac P., Beranek M., et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult. Scler. 2009, 15:316-322.
14. Black R.A., Durie F.H., Otten-Evans C., Miller R., Slack J.L., Lynch D.H., et al. Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP. Biochem. Biophys. Res. Commun. 1996, 225:400-405.
15. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
16. Bosschaerts T., Morias Y., Stijlemans B., Herin M., Porta C., Sica A., et al. IL-10 limits production of pathogenic TNF by M1 myeloid cells through induction of nuclear NF-kappaB p50 member in Trypanosoma congolense infection-resistant C57BL/6 mice. Eur. J. Immunol. 2011, 41:3270-3280.
17. Bottcher T., Spreer A., Azeh I., Nau R., Gerber J. Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis. Neurosci. Lett. 2003, 338:201-204.
18. Bridoux L., Etique N., Lambert E., Thevenard J., Sowa M.L., Belloy N., et al. A crucial role for Lyn in TIMP-1 erythroid cell survival signalling pathway. FEBS Lett. 2013, 587:1524-1528.
19. Brinckerhoff C.E., Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 2002, 3:207-214.
20. Brouwer M.C., Thwaites G.E., Tunkel A.R., Van De Beek D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. Lancet 2012, 380:1684-1692.
21. Brundula V., Rewcastle N.B., Metz L.M., Bernard C.C., Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002, 125:1297-1308.
22. Buhler L.A., Samara R., Guzman E., Wilson C.L., Krizanac-Bengez L., Janigro D., et al. Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis. BMC Neurosci. 2009, 10:17.
23. Castelhano A.L., Billedeau R., Dewdney N., Donnelly S., Horne S., Kurz L.J., et al. Novel indolactam-based inhibitors of matrix metalloproteinases. Bioorg. Med. Chem. Lett. 1995, 5:1415-1420.
24. Cesca F., Baldelli P., Valtorta F., Benfenati F. The synapsins: key actors of synapse function and plasticity. Prog. Neurobiol. 2010, 91:313-348.
25. Chaillan F.A., Rivera S., Marchetti E., Jourquin J., Werb Z., Soloway P.D., Khrestchatisky M., Roman F.S. Involvement of tissue inhibition of metalloproteinases-1 in learning and memory in mice. Behav. Brain Res. 2006, 173:191-198.
26. Chandran A., Herbert H., Misurski D., Santosham M. Long-term sequelae of childhood bacterial meningitis: an underappreciated problem. Pediatr. Infect. Dis. J. 2011, 30:3-6.
27. Choi S.H., Veeraraghavalu K., Lazarov O., Marler S., Ransohoff R.M., Ramirez J.M., et al. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 2008, 59:568-580.
28. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 2008, 40:1362-1378.
29. Clements J.M., Cossins J.A., Wells G.M., Corkill D.J., Helfrich K., Wood L.M., et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 1997, 74:85-94.
30. Colovic M., Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 791:337-343.
31. Comabella M., Rio J., Espejo C., Ruiz De Villa M., Al-Zayat H., Nos C., et al. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 2009, 130:145-150.
32. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
33. Crocker S.J., Whitmire J.K., Frausto R.F., Chertboonmuang P., Soloway P.D., Whitton J.L., Campbell I.L. Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am. J. Pathol. 2006, 169:2104-2116.
34. Crouch P.J., Tew D.J., Du T., Nguyen D.N., Caragounis A., Filiz G., et al. Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation. J. Neurochem. 2009, 108:1198-1207.
35. Cuzner M.L., Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 1999, 94:1-14.
36. Deb S., Wenjun Zhang J., Gottschall P.E. Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res. 2003, 970:205-213.
37. Devel L., Garcia S., Czarny B., Beau F., Lajeunesse E., Vera L., et al. Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation. J. Biol. Chem. 2010, 285:35900-35909.
38. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., Van Den Oord J., et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 1999, 104:1507-1515.
39. Edmond K., Dieye Y., Griffiths U.K., Fleming J., Ba O., Diallo N., et al. Prospective cohort study of disabling sequelae and quality of life in children with bacterial meningitis in urban Senegal. Pediatr. Infect. Dis. J. 2010, 29:1023-1029.
40. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
41. Elkington P.T., O'kane C.M., Friedland J.S. The paradox of matrix metalloproteinases in infectious disease. Clin. Exp. Immunol. 2005, 142:12-20.
42. Engelhardt B., Ransohoff R.M. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012, 33:579-589.
43. Fager N., Jaworski D.M. Differential spatial distribution and temporal regulation of tissue inhibitor of metalloproteinase mRNA expression during rat central nervous system development. Mech. Dev. 2000, 98:105-109.
44. Fainardi E., Castellazzi M., Tamborino C., Trentini A., Manfrinato M.C., Baldi E., et al. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult. Scler. 2009, 15:547-554.
45. Ferguson T.A., Muir D. MMP-2 and MMP-9 increase the neurite-promoting potential of schwann cell basal laminae and are upregulated in degenerated nerve. Mol. Cell. Neurosci. 2000, 16:157-167.
46. Fingleton B. MMPs as therapeutic targets-still a viable option?. Semin. Cell Dev. Biol. 2008, 19:61-68.
47. Fisher J.F., Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev. 2006, 25:115-136.
48. Folgueras A.R., Fueyo A., Garcia-Suarez O., Cox J., Astudillo A., Tortorella P., et al. Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J. Biol. Chem. 2008, 283:9465-9474.
49. Forbes C., Shi Q., Fisher J.F., Lee M., Hesek D., Llarrull L.I., et al. Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases. Chem. Biol. Drug Des. 2009, 74:527-534.
50. Fujita-Hamabe W., Tokuyama S. The involvement of cleavage of neural cell adhesion molecule in neuronal death under oxidative stress conditions in cultured cortical neurons. Biol. Pharm. Bull. 2012, 35:624-628.
51. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 2001, 50:443-451.
52. Garcia-Alloza M., Prada C., Lattarulo C., Fine S., Borrelli L.A., Betensky R., et al. Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J. Neurochem. 2009, 109:1636-1647.
53. Gerber J., Nau R. Mechanisms of injury in bacterial meningitis. Curr. Opin. Neurol. 2010, 23:312-318.
54. Gerber J., Bottcher T., Hahn M., Siemer A., Bunkowski S., Nau R. Increased mortality and spatial memory deficits in TNF-alpha-deficient mice in ceftriaxone-treated experimental pneumococcal meningitis. Neurobiol. Dis. 2004, 16:133-138.
55. Gianinazzi C., Grandgirard D., Imboden H., Egger L., Meli D.N., Bifrare Y.D., Joss P.C., Tauber M.G., Borner C., Leib S.L. Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis. Acta Neuropathol. 2003, 105:499-507.
56. Gijbels K., Proost P., Masure S., Carton H., Billiau A., Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 1993, 36:432-440.
57. Giraudon P., Bernard A., Malcus C., Dufay N., Desgranges C., Belin M.F. Retroviral infection (HTLV-I) induces cytokine-regulated immunomodulation and cytotoxicity of medulloblastoma cells. J. Neuropathol. Exp. Neurol. 1995, 54:165-174.
58. Giraudon P., Thomasset N., Bernard A., Verrier B., Belin M.F. Induction of MMP9 (92kDa gelatinase) activity and expression of tissue inhibitor of metalloproteinase-2 mRNA (TIMP-2) in primitive neuroectodermal cells infected with retrovirus HTLV-I. Eur. J. Neurosci. 1995, 7:841-848.
59. Giraudon P., Buart S., Bernard A., Thomasset N., Belin M.F. Extracellular matrix-remodeling metalloproteinases and infection of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I). Prog. Neurobiol. 1996, 49:169-184.
60. Giraudon P., Buart S., Bernard A., Belin M.F. Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): possible involvement in neurodegenerative processes. Mol. Psychiatry 1997, 2:107-110. 184.
61. Gold S.M., Sasidhar M.V., Morales L.B., Du S., Sicotte N.L., Tiwari-Woodruff S.K., Voskuhl R.R. Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab. Invest. 2009, 89:1076-1083.
62. Golub L.M., Ramamurthy N., Mcnamara T.F., Gomes B., Wolff M., Casino A., et al. Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. J. Periodontal Res. 1984, 19:651-655.
63. Goncalves Dasilva A., Yong V.W. Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation. Am. J. Pathol. 2009, 174:898-909.
64. Gooyit M., Suckow M.A., Schroeder V.A., Wolter W.R., Mobashery S., Chang M. Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier. ACS Chem. Neurosci. 2012, 3:730-736.
65. Graesser D., Mahooti S., Haas T., Davis S., Clark R.B., Madri J.A. The interrelationship of alpha4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis. Lab. Invest. 1998, 78:1445-1458.
66. Grandgirard D., Oberson K., Buhlmann A., Gaumann R., Leib S.L. Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 2010, 54:1323-1326.
67. Grandgirard D., Gaumann R., Coulibaly B., Dangy J.P., Sie A., Junghanss T., Schudel H., Pluschke G., Leib S.L. The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis. Mediators Inflamm. 2013, 2013:312476.
68. Green J.A., Thi Hong Chau T., Farrar J.J., Friedland J.S., Thwaites G.E. CNS infection, CSF matrix metalloproteinase concentrations, and clinical/laboratory features. Neurology 2011, 76:577-579.
69. Gross J., Lapiere C.M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. USA 1962, 48:1014-1022.
70. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002, 297:1186-1190.
71. Gu Z., Cui J., Brown S., Fridman R., Mobashery S., Strongin A.Y., Lipton S.A. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 2005, 25:6401-6408.
72. Guo S., Wang S., Kim W.J., Lee S.R., Frosch M.P., Bacskai B.J., et al. Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes. Brain Res. 2006, 1111:222-226.
73. Guo Z., Sun X., He Z., Jiang Y., Zhang X. Role of matrix metalloproteinase-9 in apoptosis of hippocampal neurons in rats during early brain injury after subarachnoid hemorrhage. Neurol. Sci. 2010, 31:143-149.
74. Hadass O., Tomlinson B.N., Gooyit M., Chen S., Purdy J.J., Walker J.M., et al. Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury. PLoS One 2013, 8:e76904.
75. Hadler-Olsen E., Fadnes B., Sylte I., Uhlin-Hansen L., Winberg J.O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011, 278:28-45.
76. Hanemaaijer R., Sorsa T., Konttinen Y.T., Ding Y., Sutinen M., Visser H., et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J. Biol. Chem. 1997, 272:31504-31509.
77. Hartung H.P., Kieseier B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 2000, 107:140-147.
78. Hernandez-Guillamon M., Delgado P., Ortega L., Pares M., Rosell A., Garcia-Bonilla L., et al. Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25-35 fragment. J. Neurosci. Res. 2009, 87:2115-2125.
79. Hernandez-Guillamon M., Mawhirt S., Fossati S., Blais S., Pares M., Penalba A., et al. Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells. J. Biol. Chem. 2010, 285:27144-27158.
80. Hewson A.K., Smith T., Leonard J.P., Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 1995, 44:345-349.
81. Higashi S., Miyazaki K. Identification of a region of beta-amyloid precursor protein essential for its gelatinase A inhibitory activity. J. Biol. Chem. 2003, 278:14020-14028.
82. Higashi S., Miyazaki K. Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. Biochemistry 2003, 42:6514-6526.
83. Hoe H.S., Cooper M.J., Burns M.P., Lewis P.A., Van Der Brug M., Chakraborty G., et al. The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J. Neurosci. 2007, 27:10895-10905.
84. Hu J., Van Den Steen P.E., Sang Q.X., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 2007, 6:480-498.
85. Hu W., Metselaar J., Ben L.H., Cravens P.D., Singh M.P., Frohman E.M., et al. PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS One 2009, 4:e4151.
86. Janser P., Neumann U., Miltz W., Feifel R., Buhl T. A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg. Med. Chem. Lett. 2006, 16:2632-2636.
87. Jaworski D.M. Differential regulation of tissue inhibitor of metalloproteinase mRNA expression in response to intracranial injury. Glia 2000, 30:199-208.
88. Jaworski D.M., Boone J., Caterina J., Soloway P., Falls W.A. Prepulse inhibition and fear-potentiated startle are altered in tissue inhibitor of metalloproteinase-2 (TIMP-2) knockout mice. Brain Res. 2005, 1051:81-89.
89. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., et al. ApoE promotes the proteolytic degradation of A beta. Neuron 2008, 58:681-693.
90. Jiang J.Y., Jia F., Yin Y., Gao G., Wang Y., Cen L. MMP-9 inhibitor SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat. J. Neurotrauma 2014, 31:1225-1234.
91. Jourquin J., Tremblay E., Decanis N., Charton G., Hanessian S., Chollet A.M., Le Diguardher T., Khrestchatisky M., Rivera S. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur. J. Neurosci. 2003, 18:1507-1517.
92. Jourquin J., Tremblay E., Bernard A., Charton G., Chaillan F.A., Marchetti E., Roman F.S., Soloway P.D., Dive V., Yiotakis A., Khrestchatisky M., Rivera S. Tissue inhibitor of metalloproteinases-1 (TIMP-1) modulates neuronal death, axonal plasticity, and learning and memory. Eur. J. Neurosci. 2005, 22:2569-2578.
93. Jung S.S., Zhang W., Van Nostrand W.E. Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J. Neurochem. 2003, 85:1208-1215.
94. Kaczmarek L., Lapinska-Dzwonek J., Szymczak S. Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections?. EMBO J. 2002, 21:6643-6648.
95. Kandagaddala L.D., Kang M.J., Chung B.C., Patterson T.A., Kwon O.S. Expression and activation of matrix metalloproteinase-9 and NADPH oxidase in tissues and plasma of experimental autoimmune encephalomyelitis in mice. Exp. Toxicol. Pathol. 2012, 64:109-114.
96. Kar S., Subbaram S., Carrico P.M., Melendez J.A. Redox-control of matrix metalloproteinase-1: a critical link between free radicals, matrix remodeling and degenerative disease. Respir. Physiol. Neurobiol. 2010, 174:299-306.
97. Khrestchatisky M., Jourquin J., Ogier C., Charton G., Bernard A., Tremblay E., Rivera S. Matrix metalloproteinases and their inhibitors, modulators of neuro-immune interactions and of pathophysiological processes in the nervous system. J. Soc. Biol. 2003, 197:133-144.
98. Kieseier B.C., Kiefer R., Clements J.M., Miller K., Wells G.M., Schweitzer T., Gearing A.J., Hartung H.P. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998, 121(Pt. 1):159-166.
99. Kieseier B.C., Paul R., Koedel U., Seifert T., Clements J.M., Gearing A.J., et al. Differential expression of matrix metalloproteinases in bacterial meningitis. Brain 1999, 122:1579-1587.
100. Kim K.S. Pathogenesis of bacterial meningitis: from bacteriaemia to neuronal injury. Nat. Rev. Neurosci. 2003, 4:376-385.
101. Kim K.S. Acute bacterial meningitis in infants and children. Lancet Infect. Dis. 2010, 10:32-42.
102. Klein M., Koedel U., Pfister H.W., Kastenbauer S. Morphological correlates of acute and permanent hearing loss during experimental pneumococcal meningitis. Brain Pathol. 2003, 13:123-132.
103. Koedel U., Scheld W.M., Pfister H.W. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect. Dis. 2002, 2:721-736.
104. Koedel U., Angele B., Rupprecht T., Wagner H., Roggenkamp A., Pfister H.W., et al. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J. Immunol. 2003, 170:438-444.
105. Koistinaho M., Malm T.M., Kettunen M.I., Goldsteins G., Starckx S., Kauppinen R.A., et al. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J. Cereb. Blood Flow Metab. 2005, 25:460-467.
106. Kolb S.A., Lahrtz F., Paul R., Leppert D., Nadal D., Pfister H.W., Fontana A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J. Neuroimmunol. 1998, 84:143-150.
107. Konopacki F.A., Rylski M., Wilczek E., Amborska R., Detka D., Kaczmarek L., Wilczynski G.M. Synaptic localization of seizure-induced matrix metalloproteinase-9 mRNA. Neuroscience 2007, 150:31-39.
108. Koster-Rasmussen R., Korshin A., Meyer C.N. Antibiotic treatment delay and outcome in acute bacterial meningitis. J. Infect. 2008, 57:449-454.
109. Kuhn P.H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29:3020-3032.
110. Larsen P.H., Dasilva A.G., Conant K., Yong V.W. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci. 2006, 26:2207-2214.
111. Lee C.Z., Yao J.S., Huang Y., Zhai W., Liu W., et al. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J. Cereb. Blood Flow Metab. 2006, 26:1157-1164.
112. Leib S.L., Leppert D., Clements J., Tauber M.G. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect. Immun. 2000, 68:615-620.
113. Leib S.L., Clements J.M., Lindberg R.L., Heimgartner C., Loeffler J.M., Pfister L.A., Tauber M.G., Leppert D. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 2001, 124:1734-1742.
114. Leib S.L., Heimgartner C., Bifrare Y.D., Loeffler J.M., Taauber M.G. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr. Res. 2003, 54:353-357.
115. Leppert D., Leib S.L., Grygar C., Miller K.M., Schaad U.B., Hollander G.A. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin. Infect. Dis. 2000, 31:80-84.
116. Leppert D., Lindberg R.L., Kappos L., Leib S.L. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Brain Res. Rev. 2001, 36:249-257.
117. Liao M.C., Van Nostrand W.E. Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro. Biochemistry 2010, 49:1127-1136.
118. Lichtinghagen R., Seifert T., Kracke A., Marckmann S., Wurster U., Heidenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J. Neuroimmunol. 1999, 99:19-26.
119. Liechti F.D., Grandgirard D., Leppert D., Leib S.L. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect. Immun. 2014, 82:1710-1718.
120. Lindberg R.L., Sorsa T., Tervahartiala T., Hoffmann F., Mellanen L., Kappos L., Schaad U.B., Leib S.L., Leppert D. Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children. Neuropathol. Appl. Neurobiol. 2006, 32:304-317.
121. Liu X., Han Q., Sun R., Li Z. Dexamethasone regulation of matrix metalloproteinase expression in experimental pneumococcal meningitis. Brain Res. 2008, 1207:237-243.
122. Loeffler J.M., Ringer R., Hablutzel M., Tauber M.G., Leib S.L. The free radical scavenger alpha-phenyl-tert-butyl nitrone aggravates hippocampal apoptosis and learning deficits in experimental pneumococcal meningitis. J. Infect. Dis. 2001, 183:247-252.
123. Lorenzl S., Albers D.S., Relkin N., Ngyuen T., Hilgenberg S.L., Chirichigno J., et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem. Int. 2003, 43:191-196.
124. Machida C.M., Rodland K.D., Matrisian L., Magun B.E., Ciment G. NGF induction of the gene encoding the protease transin accompanies neuronal differentiation in PC12. Neuron 1989, 2:1587-1596.
125. Marchant D.J., Bellac C.L., Moraes T.J., Wadsworth S.J., Dufour A., Butler G.S., et al. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nat. Med. 2014, 20:493-502.
126. Marshall N.F., Dahmus G.K., Dahmus M.E. Regulation of carboxyl-terminal domain phosphatase by HIV-1 tat protein. J. Biol. Chem. 1998, 273:31726-31730.
127. Maskos K., Fernandez-Catalan C., Huber R., Bourenkov G.P., Bartunik H., Ellestad G.A., et al. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proc. Natl. Acad. Sci. USA 1998, 95:3408-3412.
128. Mast A.E., Enghild J.J., Nagase H., Suzuki K., Pizzo S.V., Salvesen G. Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin). J. Biol. Chem. 1991, 266:15810-15816.
129. Mcintyre P.B., O'brien K.L., Greenwood B., Van De Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet 2012, 380:1703-1711.
130. Meighan S.E., Meighan P.C., Choudhury P., Davis C.J., Olson M.L., Zornes P.A., et al. Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J. Neurochem. 2006, 96:1227-1241.
131. Meli D.N., Christen S., Leib S.L. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J. Infect. Dis. 2003, 187:1411-1415.
132. Meli D.N., Loeffler J.M., Baumann P., Neumann U., Buhl T., Leppert D., Leib S.L. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex. J. Neuroimmunol. 2004, 151:6-11.
133. Meli D.N., Coimbra R.S., Erhart D.G., Loquet G., Bellac C.L., Tauber M.G., Neumann U., Leib S.L. Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect. Immun. 2006, 74:3890-3896.
134. Miki T., Takegami Y., Okawa K., Muraguchi T., Noda M., Takahashi C. The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways. J. Biol. Chem. 2007, 282:12341-12352.
135. Milward E., Kim K.J., Szklarczyk A., Nguyen T., Melli G., Nayak M., et al. Cleavage of myelin associated glycoprotein by matrix metalloproteinases. J. Neuroimmunol. 2008, 193:140-148.
136. Mizoguchi H., Takuma K., Fukuzaki E., Ibi D., Someya E., Akazawa K.H., et al. Matrix metalloprotease-9 inhibition improves amyloid beta-mediated cognitive impairment and neurotoxicity in mice. J. Pharmacol. Exp. Ther. 2009, 331:14-22.
137. Mook-Kanamori B.B., Geldhoff M., Van Der Poll T., Van De Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin. Microbiol. Rev. 2011, 24:557-591.
138. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
139. Mott J.D., Thomas C.L., Rosenbach M.T., Takahara K., Greenspan D.S., Banda M.J. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J. Biol. Chem. 2000, 275:1384-1390.
140. Mroczko B., Groblewska M., Zboch M., Kulczynska A., Koper O.M., Szmitkowski M., et al. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease. J. Alzheimers Dis. 2014, 40:351-357.
141. Mun-Bryce S., Rosenberg G.A. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am. J. Physiol. 1998, 274:R1203-R1211.
142. Muraguchi T., Takegami Y., Ohtsuka T., Kitajima S., Chandana E.P., Omura A., et al. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. Nat. Neurosci. 2007, 10:838-845.
143. Murase S., Mckay R.D. Matrix metalloproteinase-9 regulates survival of neurons in newborn hippocampus. J. Biol. Chem. 2012, 287:12184-12194.
144. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011, 12:233.
145. Nagy V., Bozdagi O., Matynia A., Balcerzyk M., Okulski P., Dzwonek J., et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J. Neurosci. 2006, 26:1923-1934.
146. Natchus M.G., Cheng M., Wahl C.T., Pikul S., Almstead N.G., Bradley R.S., et al. Design and synthesis of conformationally-constrained MMP inhibitors. Bioorg. Med. Chem. Lett. 1998, 8:2077-2080.
147. Nedivi E., Hevroni D., Naot D., Israeli D., Citri Y. Numerous candidate plasticity-related genes revealed by differential cDNA cloning. Nature 1993, 363:718-722.
148. Niimi N., Kohyama K., Matsumoto Y. Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases. Neuropathology 2013, 33:612-620.
149. Nygardas P.T., Hinkkanen A.E. Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 2002, 128:245-254.
150. Ogier C., Creidy R., Boucraut J., Soloway P.D., Khrestchatisky M., Rivera S. Astrocyte reactivity to Fas activation is attenuated in TIMP-1 deficient mice, an in vitro study. BMC Neurosci. 2005, 6:68.
151. Ogier C., Bernard A., Chollet A.M., Le Diguardher T., Hanessian S., Charton G., Khrestchatisky M., Rivera S. Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins. Glia 2006, 54:272-284.
152. Oh L.Y., Larsen P.H., Krekoski C.A., Edwards D.R., Donovan F., Werb Z., Yong V.W. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J. Neurosci. 1999, 19:8464-8475.
153. Ohsawa I., Takamura C., Morimoto T., Ishiguro M., Kohsaka S. Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells. Eur. J. Neurosci. 1999, 11:1907-1913.
154. Okulski P., Jay T.M., Jaworski J., Duniec K., Dzwonek J., Konopacki F.A., et al. TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol. Psychiatry 2007, 62:359-362.
155. Opdenakker G., Van Den Steen P.E., Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001, 22:571-579.
156. Ould-Yahoui A., Tremblay E., Sbai O., Ferhat L., Bernard A., Charrat E., Gueye Y., Lim N.H., Brew K., Risso J.J., Dive V., Khrestchatisky M., Rivera S. A new role for TIMP-1 in modulating neurite outgrowth and morphology of cortical neurons. PLoS One 2009, 4:e8289.
157. Pardridge W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 2012, 32:1959-1972.
158. Pashenkov M., Teleshova N., Kouwenhoven M., Smirnova T., Jin Y.P., Kostulas V., et al. Recruitment of dendritic cells to the cerebrospinal fluid in bacterial neuroinfections. J. Neuroimmunol. 2002, 122:106-116.
159. Paul R., Lorenzl S., Koedel U., Sporer B., Vogel U., Frosch M., Pfister H.W. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann. Neurol. 1998, 44:592-600.
160. Peress N., Perillo E., Zucker S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 1995, 54:16-22.
161. Perez-Martinez L., Jaworski D.M. Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal. J. Neurosci. 2005, 25:4917-4929.
162. Piccini A., Ciotti M.T., Vitolo O.V., Calissano P., Tabaton M., Galli C. Endogenous APP derivatives oppositely modulate apoptosis through an autocrine loop. Neuroreport 2000, 11:1375-1379.
163. Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 2004, 113:1456-1464.
164. Prikk K., Maisi P., Pirila E., Sepper R., Salo T., Wahlgren J., Sorsa T. In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. J. Pathol. 2001, 194:232-238.
165. Py N.A., Bonnet A.E., Bernard A., Marchalant Y., Charrat E., Checler F., Khrestchatisky M., Baranger K., Rivera S. Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer's disease: evidence for a pro-amyloidogenic role of MT1-MMP. Front. Aging Neurosci. 2014, eCollection 2014. 10.3389/fnagi.2014.00247.
166. Rao B.G. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des. 2005, 11:295-322.
167. Rao J.S., Yamamoto M., Mohaman S., Gokaslan Z.L., Fuller G.N., Stetler-Stevenson W.G., et al. Expression and localization of 92kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin. Exp. Metastasis 1996, 14:12-18.
168. Rivera S., Tremblay E., Timsit S., Canals O., Ben-Ari Y., Khrestchatisky M. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J. Neurosci. 1997, 17:4223-4235.
169. Rivera S., Ogier C., Jourquin J., Timsit S., Szklarczyk A.W., Miller K., Gearing A.J., Kaczmarek L., Khrestchatisky M. Gelatinase B and TIMP-1 are regulated in a cell- and time dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur. J. Neurosci. 2002, 15:19-32.
170. Rivera S., Khrestchatisky M., Kaczmarek L., Rosenberg G.A., Jaworski D.M. Metzincin proteases and their inhibitors, foes or friends in nervous system physiology?. J. Neurosci. 2010, 30:15337-15357.
171. Roine I., Pelkonen T., Bernardino L., Lauhio A., Tervahartiala T., Lappalainen M., et al. Predictive value of cerebrospinal fluid matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 concentrations in childhood bacterial meningitis. Pediatr. Infect. Dis. J. 2014, 33:675-679.
172. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 2002, 39:279-291.
173. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009, 8:205-216.
174. Rosenberg G.A., Mun-Bryce S., Wesley M., Kornfeld M. Collagenase-induced intracerebral hemorrhage in rats. Stroke 1990, 21:801-807.
175. Rosenberg G.A., Kornfeld M., Estrada E., Kelley R.O., Liotta L.A., Stetler-Stevenson W.G. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 1992, 576:203-207.
176. Rosenberg G.A., Estrada E.Y., Dencoff J.E., Stetler-Stevenson W.G. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res. 1995, 703:151-155.
177. Rosenberg G.A., Estrada E.Y., Dencoff J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998, 29:2189-2195.
178. Sbai O., Ferhat L., Bernard A., Gueye Y., Ould-Yahoui A., Thiolloy S., Charrat E., Charton G., Tremblay E., Risso J.J., Chauvin J.P., Arsanto J.P., Rivera S., Khrestchatisky M. Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells. Mol. Cell. Neurosci. 2008, 39:549-568.
179. Sbai O., Ould-Yahoui A., Ferhat L., Gueye Y., Bernard A., Charrat E., Mehanna A., Risso J.J., Chauvin J.P., Fenouillet E., Rivera S., Khrestchatisky M. Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes. Glia 2010, 58:344-366.
180. Schubert-Unkmeir A., Konrad C., Slanina H., Czapek F., Hebling S., Frosch M. Neisseria meningitidis induces brain microvascular endothelial cell detachment from the matrix and cleavage of occludin: a role for MMP-8. PLoS Pathog. 2010, 6:e1000874.
181. Sellner J., Leib S.L. In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation. Neurobiol. Dis. 2006, 21:647-656.
182. Sellner J., Simon F., Meyding-Lamade U., Leib S.L. Herpes-simplex virus encephalitis is characterized by an early MMP-9 increase and collagen type IV degradation. Brain Res. 2006, 1125:155-162.
183. Selvais C., D'auria L., Tyteca D., Perrot G., Lemoine P., Troeberg L., et al. Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J. 2011, 25:2770-2781.
184. Shapiro S., Miller A., Lahat N., Sobel E., Lerner A. Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. J. Neurol. Sci. 2003, 206:43-48.
185. Shiryaev S.A., Savinov A.Y., Cieplak P., Ratnikov B.I., Motamedchaboki K., Smith J.W., Strongin A.Y. Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One 2009, 4:e4952.
186. Small P.M., Tauber M.G., Hackbarth C.J., Sande M.A. Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. Infect. Immun. 1986, 52:484-487.
187. Song W., Peng Z., Gooyit M., Suckow M.A., Schroeder V.A., Wolter W.R., et al. Water-soluble MMP-9 inhibitor prodrug generates active metabolites that cross the blood-brain barrier. ACS Chem. Neurosci. 2013, 4:1168-1173.
188. Sporer B., Paul R., Koedel U., Grimm R., Wick M., Goebel F.D., Pfister H.W. Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients. J. Infect. Dis. 1998, 178:854-857.
189. Stadelmann C., Bruck W. Interplay between mechanisms of damage and repair in multiple sclerosis. J. Neurol. 2008, 255(Suppl. 1):12-18.
190. Stetler-Stevenson W.G. Progelatinase A activation during tumor cell invasion. Invasion Metastasis 1994, 14:259-268.
191. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 1995, 270:5331-5338.
192. Sulik A., Chyczewski L. Immunohistochemical analysis of MMP-9, MMP-2 and TIMP-1, TIMP-2 expression in the central nervous system following infection with viral and bacterial meningitis. Folia Histochem. Cytobiol. 2008, 46:437-442.
193. Sulik A., Wojtkowska M., Oldak E. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of children with echovirus type 30 and mumps meningitis. Scand. J. Immunol. 2008, 68:323-327.
194. Szklarczyk A., Lapinska J., Rylski M., Mckay R.D., Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J. Neurosci. 2002, 22:920-930.
195. Tai L.M., Mehra S., Shete V., Estus S., Rebeck G.W., Bu G., Ladu M.J. Soluble apoE/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol. Neurodegener. 2014, 9:2.
196. Takagi S., Simizu S., Osada H. RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res. 2009, 69:1502-1508.
197. Talamagas A.A., Efthimiopoulos S., Tsilibary E.C., Figueiredo-Pereira M.E., Tzinia A.K. Abeta(1-40)-induced secretion of matrix metalloproteinase-9 results in sAPPalpha release by association with cell surface APP. Neurobiol. Dis. 2007, 28:304-315.
198. Tan H.K., Heywood D., Ralph G.S., Bienemann A., Baker A.H., Uney J.B. Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol. Cell. Neurosci. 2003, 22:98-106.
199. Tao P., Fisher J.F., Mobashery S., Schlegel H.B. DFT studies of the ring-opening mechanism of SB-3CT, a potent inhibitor of matrix metalloproteinase 2. Org. Lett. 2009, 11:2559-2562.
200. Tarrago T., Kichik N., Claasen B., Prades R., Teixido M., Giralt E. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg. Med. Chem. 2008, 16:7516-7524.
201. Thigpen M.C., Whitney C.G., Messonnier N.E., Zell E.R., Lynfield R., Hadler J.L., et al. Bacterial meningitis in the United States, 1998-2007. N. Engl. J. Med. 2011, 364:2016-2025.
202. Thirumangalakudi L., Samany P.G., Owoso A., Wiskar B., Grammas P. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J. Alzheimers Dis. 2006, 10:111-118.
203. Thorne M., Moore C.S., Robertson G.S. Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice. J. Neuroimmunol. 2009, 211:92-100.
204. Toft-Hansen H., Nuttall R.K., Edwards D.R., Owens T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J. Immunol. 2004, 173:5209-5218.
205. Van De Beek D., De Gans J., Spanjaard L., Weisfelt M., Reitsma J.B., Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N. Engl. J. Med. 2004, 351:1849-1859.
206. Van Furth A.M., Roord J.J., Van Furth R. Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. Infect. Immun. 1996, 64:4883-4890.
207. Van Horssen J., Vos C.M., Admiraal L., Van Haastert E.S., Montagne L., Van Der Valk P., et al. Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol. Appl. Neurobiol. 2006, 32:585-593.
208. Vlieghe P., Khrestchatisky M. Peptide-based vectors for blood-brain barrier targeting and delivery of drugs to the central nervous system. Ther. Deliv. 2010, 1:489-494.
209. Vlieghe P., Khrestchatisky M. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med. Res. Rev. 2013, 33:457-516.
210. Walker E.J., Rosenberg G.A. TIMP-3 and MMP-3 contribute to delayed inflammation and hippocampal neuronal death following global ischemia. Exp. Neurol. 2009, 216:122-131.
211. Waubant E., Goodkin D.E., Gee L., Bacchetti P., Sloan R., Stewart T., et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999, 53:1397-1401.
212. Waubant E., Gee L., Miller K., Stabler G., Goodkin D. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. 2001, 21:181-185.
213. Weaver A., Goncalves Da Silva A., Nuttall R.K., Edwards D.R., Shapiro S.D., Rivest S., Yong V.W. An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB J. 2005, 19:1668-1670.
214. Wetzel M., Rosenberg G.A., Cunningham L.A. Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis. Eur. J. Neurosci. 2003, 18:1050-1060.
215. Wilczynski G.M., Konopacki F.A., Wilczek E., Lasiecka Z., Gorlewicz A., Michaluk P., et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J. Cell Biol. 2008, 180:1021-1035.
216. Xing C., Levchenko T., Guo S., Stins M., Torchilin V.P., Lo E.H. Delivering minocycline into brain endothelial cells with liposome-based technology. J. Cereb. Blood Flow Metab. 2012, 32:983-988.
217. Yan P., Hu X., Song H., Yin K., Bateman R.J., Cirrito J.R., et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 2006, 281:24566-24574.
218. Yin K.-J., Cirrito J.R., Yan P., Hu X., Xiao Q., Pan X., et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J. Neurosci. 2006, 26:10939-10948.
219. Yong V.W., Wells J., Giuliani F., Casha S., Power C., Metz L.M. The promise of minocycline in neurology. Lancet Neurol. 2004, 3:744-751.
220. Yong V.W., Giuliani F., Xue M., Bar-Or A., Metz L.M. Experimental models of neuroprotection relevant to multiple sclerosis. Neurology 2007, 68:S32-S37. discussion S43-S54.
221. Yushchenko M., Weber F., Mader M., Scholl U., Maliszewska M., Tumani H., et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J. Neuroimmunol. 2000, 110:244-251.
222. Zhang J.W., Deb S., Gottschall P.E. Regional and age-related expression of gelatinases in the brains of young and old rats after treatment with kainic acid. Neurosci. Lett. 2000, 295:9-12.
223. Zhao L., Lin S., Bales K.R., Gelfanova V., Koger D., Delong C., et al. Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism. J. Neurosci. 2009, 29:3603-3612.
224. Zhou J., Stohlman S.A., Atkinson R., Hinton D.R., Marten N.W. Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection. J. Virol. 2002, 76:7374-7384.
225. Zhou J., Marten N.W., Bergmann C.C., Macklin W.B., Hinton D.R., Stohlman S.A. Expression of matrix metalloproteinases and their tissue inhibitor during viral encephalitis. J. Virol. 2005, 79:4764-4773.
226. Zuo J., Ferguson T.A., Hernandez Y.J., Stetler-Stevenson W.G., Muir D. Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin sulfate proteoglycan. J. Neurosci. 1998, 18:5203-5211.
227. Zwahlen A., Nydegger U.E., Vaudaux P., Lambert P.H., Waldvogel F.A. Complement-mediated opsonic activity in normal and infected human cerebrospinal fluid: early response during bacterial meningitis. J. Infect. Dis. 1982, 145:635-646.